University of Chicago
Chicago, IL
Fellowship - Hematology & Oncology
1983
University of Chicago
Chicago. IL
Residency - Internal Medicine
1980
Stanford University School of Medicine
Stanford, CA
MD - Medicine
1977
King's College, University of Cambridge
Cambridge, England
- Chemistry
1973
Dartmouth College
Hanover, NH
AB - Chemistry
1972
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Mar 05; 1-4.
PMID: 38441062
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts. Leukemia. 2024 02; 38(2):389-392.
PMID: 38263433
Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL.
Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL. Blood. 2024 Jan 12.
PMID: 38215395
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
PMID: 38039510
Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis.
Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis. Blood Cancer Discov. 2023 Dec 27.
PMID: 38150184
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
PMID: 38073116
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2023 Dec 01.
PMID: 38039510
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. JAMA Netw Open. 2023 Dec 01; 6(12):e2347950.
PMID: 38109114
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia. 2024 01; 38(1):45-57.
PMID: 38017103
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia. 2024 01; 38(1):58-66.
PMID: 37935977